Not Yet Recruiting
A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy
NCT06156332
- Conditions
- Advanced Solid Tumors With Neuroendocrine Differentiation
- Locations
-
Not specified